期刊文献+

2型糖尿病患者血浆肌肉抑制素与C肽相关性分析 被引量:1

Analysis of Correlation between Plasma Myostatin and C-peptide in Patients with Type 2 Diabetes Mellitus
下载PDF
导出
摘要 目的:测定2型糖尿病(Type 2 diabetes,T2D)患者血浆肌肉抑制素(Myostatin)和C肽含量的变化,探讨二者在T2D发病机制中的作用。方法:酶联免疫分析法检测42例T2D患者和20例健康体检者血浆肌肉抑制素的含量,化学发光法测定空腹C肽浓度,临床生化检测血浆中脂质、血糖和胰岛素含量。结果:与健康对照组比较,T2D患者空腹血糖、胰岛素、甘油三酯和收缩压水平显著增加(P<0.05)。T2D糖尿病患者血浆肌肉抑制素水平比健康对照组显著增加(46.22±13.78 pg/L vs 86.83±29.10 pg/L,P<0.01)。T2D患者血浆肌肉抑制素水平与血浆C肽呈显著负相关(r=-0.56,P<0.01)。结论:T2D患者血浆中肌肉抑制素水平升高,且与血浆C肽水平呈显著负相关。 Objective To investigate the correlation between plasma myostatin and C-peptide in patients with type 2 diabetes mellitus( T2D). Methods Forty-two patients with T2 D and twenty healthy volunteers were recruited in this study. The levels of plasma myostatin and fasting C-peptide were detected with ELISA and chemiluminescent,respectively. The plasma lipid,fasting plasma glucose( FPG) and serum insulin were measured. Results Compared with healthy controls,the levels of FPG,serum insulin,triglyceride and systolic pressure were significantly higer in patients with T2D( P〈0. 05). The level of plasma myostatin in T2 D patients was obviously higher than that of healthy controls( 46. 22 ± 13. 78 pg /L vs 86. 83 ± 29. 10 pg /L,P 〈0. 01). The level of plasma myostatin was negatively correlated with C-peptide level( r =-0. 56,P〈 0. 01).Conclusion The level of plasma myostatin was upregulated in patients with T2 D,which was negatively correlated with the level of C-peptide.
出处 《湖北医药学院学报》 CAS 2014年第4期343-345,共3页 Journal of Hubei University of Medicine
基金 湖北省教育厅自然科学研究项目(B20082405)
关键词 肌肉抑制素 2型糖尿病 C肽 Myostatin Type 2 diabetes C-peptide
  • 相关文献

参考文献5

二级参考文献56

  • 1Molyneaux LM, Constantino MI, McGill M, et al. Better gly- caemic control and risk reduction of diabetic complications in type 2 diabetes:comparison with the DCCT. Diabetes Res Clin Pract 1998; 42(2) :77 -83.
  • 2He BB, Wei L, Gu YJ, et al. Factors Associated with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes Mellitus. Int J Endocrinol 2012:157940 - 157947.
  • 3Mavrakanas T, Frachebois C, Soualah A, et al. C-peptide and chronic complications in patients with type-2 diabetes and the metabol- ic syndrome. Presse ivied 2009 ;38 (10) : 1399 - 1403.
  • 4Shpakov AO, Granstrem AO. C-peptide structure, fimctions and molecular mechanisms of action. Tsitologiia 2013 ;55 ( 1 ) : 16 - 27.
  • 5Kim BY,Jung CH,Mok JO,et al. Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients. Acta Diabetol 2012 ;49( 1 ) :9 - 15.
  • 6Munte CE, Vilela L, Kalbitzer HR, et al. Solution structure of human proinsulin C-peptide. FEBS J 2005 ;272 ( 16 ) :4284 -4293. k + ATP 酶.
  • 7Vague P, Coste TC, Jannot MF, et al. C-peptide, Na^+, K ( + ) -ATPase, and diabetes. Exp Diabesity Res 2004 ;5 ( 1 ) : 37 - 50.
  • 8Bo S, Gentile L, Castiglione A, Prandi V, et al. C-peptide and the risk for incident complications and mortality in type 2 diabetic pa- tients:a retrospective cohort study after a 14-year follow-up. Ear J En- docrinol 2012 ; 167 (2) : 173 - 180.
  • 9Yoon HJ, Cho YZ, Kim JY, et al. Correlations between Gluca- gon Stimulated C-peptide Levels and Microvascular Complications in Type 2 Diabetes Patients. Diabetes Metab J 2012:36(5 ) :379 - 387.
  • 10Y.W. Chen,L.Z. Cao,J.W. Ye,D.H. Zhu.Upregulation of myostatin gene expression in streptozotocininduced type 1 diabetes mice is attenuated by insulin. Biochemistry and Biophysics . 2009

共引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部